Preformed and de novo donor specific antibodies in visceral transplantation: Long-term outcome with special reference to the liver

American Journal of Transplantation

Volumn 12, Issue 11, 2012, Pages 3047-3060

  Abu Elmagd, K M ^a   Wu, G ^a   Costa, G ^a   Lunz, J ^b   Martin, L ^a   Koritsky, D A ^a   Murase, N ^a   Irish, W ^c   Zeevi, A ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Clinical Trial and Consulting Services   (United States)

Author keywords

Acute rejection; anti HLA donor specific antibodies; chronic rejection; intestinal transplantation; lymphocytotoxic crossmatch; survival

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; COMPLEMENT COMPONENT C4D; DACLIZUMAB; DONOR SPECIFIC ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ACUTE HUMORAL REJECTION; ADULT; AGED; ALLOGRAFT; ARTICLE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP TYPING; BONE MARROW; CHRONIC GRAFT REJECTION; COLD ISCHEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; GROUPS BY AGE; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; LIVER; LIVER GRAFT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE DRUG DOSE; SOLID PHASE HLA DONOR SPECIFIC ANTIBODY ASSAY; SPLENECTOMY; THROMBOCYTE COUNT;

ADULT; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINES; ISOANTIBODIES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; REFERENCE VALUES; RISK ASSESSMENT; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84868191206     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04237.x     Document Type: Article

References (67)

1. Abu-Elmagd KM, Costa G, Bond GJ, et al,. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transpl Int 2009; 1: 96-101.
2. Fishbein TM,. Intestinal transplantation. N Engl J Med 2009; 361: 998-1008.
3. Pirenne J, Kawai M,. Tolerogenic protocols for intestinal transplantation. Transpl Immunol 2004; 38: 131-137.
4. Grant D, Abu-Elmagd K, Reyes J, et al,. 2003 Report of the intestine transplant registry: A new era has dawned. Ann of Surg 2005; 241: 607-613.
5. Abu-Elmagd KM, Costa G, Bond GJ, et al,. Five hundred intestinal and multivisceral transplantation at a single center: Major advances with new challenges. Ann of Surg 2009; 250: 567-581.
6. Aberg F, Isoniemi H, Hockerstedt K,. Long-term results of liver transplantation. Scandinavia J Surg 2011; 100: 14-21.
7. Kirk AD, Turgeon NA, Iwakoshi NN,. B cells and transplantation tolerance. Nat Rev Nephrol 2010; 6: 584-593.
8. Wood KJ, Goto R,. Mechanisms of rejection: Current perspectives. Transplant 2012; 93: 1-9.
9. Thaunat O,. Humoral immunity in chronic allograft rejection: Puzzle pieces come together. Transplant Immunol 2012; 26: 101-106.
10. Kwun J, Bulut P, Kim E, et al,. The role of B cells in solid organ transplantation. Semin Immunol 2011; 24: 96-108.
11. Lachmann N, Terasaki PI, Budde K, et al,. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplant 2009; 87: 1505-1513.
12. Mao Q, Terasaki PI, Cai J, et al,. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864-871.
13. Einecke G, Sis B, Reeve J, et al,. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
14. Eng HS, Bennett G, Tsiopelas E, et al,. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by luminex predict late graft loss. Am J Transplant 2008; 8: 2335-2342.
15. Musat AI, Agni RM, Wai PY, et al,. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
16. Kozlowski T, Rubinas T, Nickeleit V, et al,. Liver-allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transplant 2011; 17: 357-368.
17. O'Leary JG, Kaneku H, Susskind BM, et al,. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection post liver transplant. Am J Transplant 2011; 11: 1868-1876.
18. Ho EK, Vlad G, Vasilescu ER, et al,. Pre-and posttransplant allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival. Human Immunol 2011; 72: 5-10.
19. Patel R, Terasaki PR,. Significance of the positive cross-match test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
20. Jeanner M, Pinn VW, Flaz MH, Winn HJ, Russell PS,. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970; 282: 111-117.
21. Bond G, Reyes J, Mazariegos G, et al,. The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival. Transplant Pro 2000; 32: 1197-1198.
22. Kao KJ, Scornik JC, Small JC,. Enzyme linked immunoassay for anti-HLA antibodies: An alternative-an alternative to panel studies by lymphocytotoxicity. Transplant 1993; 55: 192-196.
23. Colombo MB, Haworth SE, Poli F, et al,. Luminex technology for anti-HLA antibody screening: Evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom 2007; 72: 465-471.
24. Worthington JE, Robson AJ, Sheldon S, Langton A, Martin S,. A comparison of enzyme-linked immunoabsorbent assays and flow cytometry techniques for the detection of HLA specific antibodies. Hum Immunol 2001; 62: 1178-1184.
25. Wu T, Abu-Elmagd K, Bond G, Demetris AJ,. A clinicopathologic study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies. Hum Pathol 2004; 35: 1332-1339.
26. Abu-Elmagd KM, Bond G, Reyes J, Fung J,. Intestinal transplantation: A coming of age. Adv Surg 2002; 36: 65-101.
27. Abu-Elmagd KM, Fung JJ, Bueno J, et al,. Logistics and technique for procurement of intestinal, pancreatic, and hepatic grafts from the same donor. Ann of Surg 2000; 232: 680-687.
28. Abu-Elmagd K, Reyes J, Bond G, et al,. Clinical intestinal transplantation: A decade of a single center experience. Ann of Surg 2001; 234: 404-417.
29. Starzl TE, Murase N, Abu-Elmagd K, et al,. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502-1510.
30. Wu T, Abu-Elmagd K, Bond G, Nalesnik MA, Randhawa P, Demetris AJ,. A schema for histologic grading of small intestine allograft acute rejection. Transplantation 2003; 75: 1241-1243.
31. Abu-Elmagd K, Reyes J, Todo S, et al,. Clinical intestinal transplantation: New perspectives and immunologic considerations. J Am Coll Surg 1998; 186: 512-527.
32. Demetris AJ, Murase N, Lee RG, et al,. Chronic rejection: A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant 1997; 2: 27-44.
33. Parizhskaya M, Redondo C, Demetris A, et al,. Chronic rejection of small bowel grafts: A pediatric and adult study of risk factors and morphologic progression. Ped & Dev Path 2003; 6: 240-250.
34. Tait BD, Hudson F, Brewin G, Cantwell L, Holdsworth R,. Solid phase HLA antibody detection technology-Challenges in interpretation. Tissue Antigen 2010; 76: 87-95.
35. Eng HS, Bennett G, Bardy P, et al,. Clinical significance of anti-HLA antibodies detected by luminex: Enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum Immunol 2009; 70: 595-599.
36. Takemoto SK, Zeevi A, Feng S, et al,. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-1041.
37. Leffell MS, Zachary AA,. Antiallograft antibodies: Relevance, detection, and monitoring. Curr Opin Organ Transplant 2010; 15: 2-7.
38. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S,. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681-1688.
39. Amico P, Honger G, Steiger J, Schaub S,. Utility of the virtual crossmatch in solid organ transplantation. Curr Opin Organ Transplant 2009; 14: 656-661.
40. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D,. HLA antibody specification using single-antigen beads-A technical solution for the prozone effect. Transplantation 2011; 92: 510-515.
41. Gaston RS, Cecka JM, Kasiske BL, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplanation 2010; 90: 68-74.
42. Terasaki PI, Cai J,. Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008; 86: 377-383.
43. Lunz J, Ruppert KM, Cajaiba MM, et al,. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: Can c4d stains help in monitoring? Am J Transplant 2012; 12: 171-182.
44. Troxell ML, Higgins JP, Kambham N,. Evaluation of c4d staining in liver and small intestine allografts. Arch Pathol Lab Med 2006; 130: 1489-1496.
45. Hidalgo LG, Campbell RP, Sis B, et al,. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532-2541.
46. Dar W, Agarwal A, Watkins C, et al,. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplant. Am J Transplant 2011; 11: 841-847.
47. Iwaki Y, Starzl TE, Tagihashi A, et al,. Replacement of donor lymphoid tissue in human small bowel transplants under FK-506 immunosuppression. Lancet 1991; 337: 818-819.
48. Cecka JM, Zhang Q, Reed EF,. Preformed cytotoxic antibodies in potential allograft recipients: Recent data. Human Immunol 2005; 66: 343-349.
49. Reed E, Ho E, Cohen DJ, et al,. Anti-idiotypic antibodies specific for HLA in heart and kidney allograft recipients. Immunol Res 1993; 12: 1-11.
50. Cai J, Terasaki PI,. Post-transplantation antibody monitoring and HLA antibody epitope identification. Curr Opin Immunol 2008; 20: 602-606.
51. Zeevi A, Marrari M, Feingold B, Webber S, Duquesnoy RJ,. Human leukocyte antigen epitope analysis to assess complement-and non-complement-binding donor-specific antibody repertoire in a pediatric heart transplant recipient. Human Immunol 2012; 73: 48-51.
52. Duquesnoy RJ, Marrari M,. Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants. Transplant Immunol 2011; 24: 164-171.
53. Mizutani K, Terasaki P, Rosen A, et al,. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265-2272.
54. Marrari M, Duquesnoy RJ,. Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant. Transplant Immunol 2010; 22: 105-109.
55. Sacks SH, Chowdhury P, Zhou W,. Role of the complement system in rejection. Curr Opin Immunol 2003; 15: 487-492.
56. Willicombe M, Brookes P, Santos-Nunez E, et al,. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2011; 11: 470-477.
57. Willicombe M, Roufosse C, Brookes P, et al,. Antibody-mediated rejection after alemtuzumab induction: Incidence, risk factors, and predictors of poor outcome. Transplantation 2011; 92: 176-182.
58. Demetris AJ, Murase N, Nakamura K, et al,. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Seminar in Liver Disease 1992; 12: 51-59.
59. Lerut J, Sanchez-Fueyo A,. An appraisal of tolerance in liver transplantation. Am J Transplant 2006; 6: 1774-1780.
60. Charles R, Lu L, Qian S, Fung JJ,. Stromal cell-based immunotherapy in transplantation. Immunotherapy 2011; 3: 1471-1485.
61. Barth RN, Campos L, Kukuruga DL, Drachenberg C, Philosophe B,. Antibody-mediated rejection of renal allograft in combined liver-kidney transplant. Clin Transplant 2010; 24: 685-690.
62. Alqurashi S, Alsayyari AA, Abdullah K, Alwan A, Hajeer AH,. Combined liver and kidney transplantation in a highly sensitized and positively cross-matched patient. Saudi J Kidney Dis Transpl 2011; 22: 757-760.
63. Tsai HL, Island ER, Chang JW, et al,. Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation. Transplantation 2001; 92: 709-715.
64. Mazariegos GV, Superina R, Rudolph J, et al,. Current status of pediatric intestinal failure, rehabilitation, and transplantation: Summary of a colloquium. Transplantation 2011; 92: 1173-1180.
65. Farmer DG, Venick RS, Colangelo J, et al,. Pretransplant predictors of survival after intestinal transplantation: Analysis of a single-center experience of more than 100 transplants. Transplantation 2010; 90: 1574.
66. Bork K,. Human pasteurized C1-inhibitor concentrate for the treatment of hereditary angioedema due to C1-inhibitor deficiency. Expert Rev Clin Immunol 2011; 7: 723-733.
67. Kirk AD, Morrell CN, Baldwin WM,. Platelets influence vascularized organ transplants from start to finish. Am J Transplant 2009; 9: 14-22.